SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. – MGNX

The investigation concerns whether MacroGenics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On April 3, 2024, MacroGenics announced Phase 2 TAMARACK interim safety data as contained in its abstract submitted to the American Society of Clinical Oncology on February 6, 2024. The Company reported that "[p]reliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability in me ...